- Investing Ideas
- Swedish Pharmaceuticals & Biotech Healthy high growth potential
Swedish Pharmaceuticals & Biotech Healthy high growth potential
Results
6
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
6 companies
Camurus
Market Cap: SEK 36.1b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 607.00
7D
-1.7%
1Y
-5.5%
Bonesupport Holding
Market Cap: SEK 14.7b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 223.60
7D
1.5%
1Y
-28.1%
BioArctic
Market Cap: SEK 27.9b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 314.40
7D
-3.3%
1Y
44.6%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.80
7D
1.1%
1Y
-24.6%
Moberg Pharma
Market Cap: SEK 469.5m
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
MOB
SEK 9.99
7D
5.7%
1Y
9.7%
AlzeCure Pharma
Market Cap: SEK 957.0m
Operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
ALZCUR
SEK 6.94
7D
14.1%
1Y
86.1%